Overview
CURRENT LOCATION: HOME > R&D and Innovation > Overview
OVERVIEW
01

R&D Directions

02

R&D Projects

03

Intellectual Property

04

Innovative Platform

05

Innovative Talents

The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.

The company has more than 500 ongoing projects, including more than 30 Class 1 new drugs under study.

The company has 826 authorized patents, 389 invention patents and 82 overseas authorized patents.

The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, China.

The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.

While building a first-class platform for R&D and innovation, the company provides all-around service from research, development, and clinical trials to registration of new drugs.

The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.

Today, the company has more than 1,800 research and development personnel, including more than 200 doctors, and 7 experts enjoying a special allowance of The State Council.

The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.
The company has more than 500 ongoing projects, including more than 30 Class 1 new drugs under study.
The company has 826 authorized patents, 389 invention patents and 82 overseas authorized patents.The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, Chi
The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.While building a first-class platform for R&D and innovation, the
The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.Today, the company has more than 1,800 research and development personnel, including more than 200 doctors, and

Development Progress

R&D Centers

Technology Platform
Technology platform for innovative small molecule drugs

Design of novel molecules that are non-addictive and non-respiratory depressant.

Technology platform for long-acting microspheres and liposomes

Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.

Technology platform for transdermal administration

Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.

Technology platform for anti-abuse design of special drugs

Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.

Technology platform for oral sustained-release and controlled -release drugs

To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.

Technology platform for oral mucous administration

Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.

Technology Platform
Technology platform for innovative small molecule drugs

Design of novel molecules that are non-addictive and non-respiratory depressant.

Technology platform for long-acting microspheres and liposomes

Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.

Technology platform for transdermal administration

Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.

Technology platform for anti-abuse design of special drugs

Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.

Technology platform for oral sustained-release and controlled -release drugs

To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.

Technology platform for oral mucous administration

Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.

Introduction of key projects

Remazolam Besylate for Injection-Category 1 new drug

Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.

Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.

Fospropofol Disodium for Injection-Category 1 new drug

Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.

Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.

Snowbellleaf Tickclover General Flavone Capsule-Category 1 new drug

Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.

Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.

Introduction of key projects

Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.

Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.

Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.

Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.

Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.

Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.

0.326672s